We’re Building MPCs:
Next-Generation ADCs With Multiple Payloads
Catena’s Multi-Payload Conjugates™ (MPCs) Offer Unprecedented Flexibility
Our MPCs can have different payloads, of any complexity or size, at each site. Our stable C-Y Bond™ reduces off-target toxicity, and the cleavable linker offers tunable hydrophilicity for superior pharmacokinetics. MPCs provide superior activity to mono-ADCs, with tumor volume increasing with mono-ADC and control but decreasing toward tumor elimination by 35 days with MPC.
ADC, antibody-drug conjugate.
Learn more about the data
Up to 4 different payloads per antibody and drug-to-antibody ratio from 2+2 to 6+8
Explore the Future of Conjugation
CatenaBio was founded to enable the next generation of novel therapeutics by forming never-before-possible structures using our proprietary technology, which can combine therapeutics with complete freedom.
We have developed the CysTyr™ platform utilizing the novel Catenase™ enzyme, engineered to couple tyrosine residues with cysteine residues to form our proprietary C-Y Bond™.
Our platform redefines what therapeutics are possible and has successfully combined a diverse array of compounds, including toxins, isotope chelators, nucleic acids, peptides, enzymes, cytokines, nano bodies, viral capsids, and even whole cells.
Imagine if you could...
Catena’s Advantages
|
Multiple Payloads |
Payloads of Any Complexity/Size |
Scalability |
Stability |
|
| Why It Matters |
Enables superior clinical profile |
Enables therapeutic structures never before possible |
Ensures commercial production |
Minimizes off-target toxicity |
 |
||||
| Older Conjugation Strategies | ||||
| Maleimide | ||||
| Trans-glutaminase | ||||
| Sortase/Peptide Transferase | ||||
| Recent Advances | ||||
| Artificial Amino Acids | ||||
| Sugar Modification | ||||
| Older Conjugation Strategies | Recent Advances | ||||||
|---|---|---|---|---|---|---|---|
| Why It Matters | |
Maleimide | Trans-glutaminase | Sortase/Peptide Transferase | Artificial Amino Acids | Sugar Modification | |
|
Multiple Payloads |
Enables superior clinical profile |
||||||
|
Payloads of Any Complexity/Size |
Enables therapeutic structures never before possible |
||||||
|
Scalability |
Ensures commercial production |
||||||
|
Stability |
Minimizes off-target toxicity |
||||||
Because competitive approaches are complex, they are not amenable to industrial scale-up when using multiple payloads.
Modification of Cysteine-Substituted Antibodies Using Enzymatic Oxidative Coupling Reactions
February 14, 2023
Synthesis of Multi-Protein Complexes through Charge-Directed Sequential Activation of Tyrosine Residues
August 12, 2021